Zhi Tong Cai Jing·2025-11-03 01:33Core Viewpoint - The announcement of a collaboration agreement between Neurocrine Biosciences and the company for the development of NLRP3 inhibitors has positively impacted the stock price, leading to a significant increase in share value [1] Group 1: Agreement Details - On November 3, the company announced a collaboration agreement with Neurocrine Biosciences for the development of NLRP3 inhibitors aimed at treating various diseases [1] - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 drug platform outside of Greater China, while the company retains these rights within Greater China (Mainland, Hong Kong, Taiwan, Macau) [1] - The agreement has a total potential value of $881.5 million, which includes upfront payments and milestone payments related to development and commercialization progress [1] Group 2: Financial Impact - Following the announcement, the company's stock opened over 6% higher and was trading at HKD 195.9, reflecting a 6.58% increase with a trading volume of HKD 6.5627 million [1] - The potential financial benefits from the agreement could significantly enhance the company's revenue streams through milestone payments as development progresses [1]